Is Cell Point overvalued or undervalued?

As of 14 October 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in its market perception. The company is currently overvalued based on its high PE ratio of 94.95, which significantly exceeds the industry average, and a low Price to Book Value of 0.47. Additionally, the EV to EBIT stands at 18.03, further suggesting that the company's valuation is not justified by its earnings potential.
In comparison to its peers, Cell Point's valuation appears particularly stark against Elitecon International, which has a PE ratio of 378.51, and MMTC at 143.23. While both peers are also considered expensive, Cell Point's ratios reflect a concerning disconnect between its market price and fundamental performance, especially with a ROCE of only 3.63% and a ROE of 0.50%. The company's stock has underperformed significantly, with a year-to-date return of -29.72% compared to a 6.35% return for the Sensex, reinforcing the notion that Cell Point is currently overvalued.